$2.8 M

NVIV Mkt cap, 22-Jun-2018
InVivo Therapeutics Net income (Q1, 2018)-4.8 M
InVivo Therapeutics EBIT (Q1, 2018)-4.8 M
InVivo Therapeutics Cash, 31-Mar-201811.6 M

InVivo Therapeutics Financials

InVivo Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.5 m20.2 m21.5 m12.9 m

Prepaid Expenses

1.1 m184 k451 k

Current Assets

15 m20.7 m33.9 m13.8 m

PP&E

1.6 m938 k510 k

Total Assets

16.7 m21.8 m34.8 m14 m

Accounts Payable

569 k521 k1 m988 k

Current Liabilities

9.2 m3.3 m4.8 m3.1 m

Total Liabilities

10.8 m4.9 m5.8 m3.9 m

Common Stock

1 k1 k1 k

Additional Paid-in Capital

106.2 m150.5 m186 m194 m

Retained Earnings

(100.3 m)(133.6 m)(157 m)(183.9 m)

Total Equity

5.9 m16.9 m28.9 m10.1 m

EPS

0.8 1.3 0.8

Financial Leverage

2.8 x1.3 x1.2 x1.4 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

9.8 m20.9 m17.6 m24.5 m25.1 m22.1 m45.8 m41.6 m37.7 m14.4 m14.3 m16.4 m11.6 m

Prepaid Expenses

445 k378 k342 k543 k397 k268 k617 k682 k413 k940 k657 k475 k

Current Assets

10.7 m21.6 m18.3 m25.4 m25.9 m22.8 m46.7 m42.7 m38.4 m27.4 m22.9 m18 m13.1 m

PP&E

2.2 m2 m1.8 m1.4 m1.3 m1.1 m846 k736 k630 k395 k305 k190 k

Total Assets

13 m23.7 m20.3 m27 m27.3 m24 m47.7 m43.5 m39.5 m29 m23.6 m18.6 m13.3 m

Accounts Payable

704 k592 k711 k793 k953 k797 k438 k559 k556 k1 m878 k1.3 m1.2 m

Current Liabilities

2 m7.8 m4.8 m15.1 m10.3 m5.5 m4.8 m4.6 m5.5 m4.1 m3.9 m3.6 m4.1 m

Total Liabilities

3.9 m9.7 m6.7 m16.7 m11.9 m6.9 m6.2 m5.9 m6.6 m5 m4.6 m4.3 m5 m

Common Stock

1 k1 k1 k1 k1 k1 k1 k1 k1 k1 k1 k1 k

Additional Paid-in Capital

96.1 m104.7 m105.4 m126.3 m141.8 m145.9 m181.7 m183 m184.4 m187.5 m188.9 m193.5 m197 m

Retained Earnings

(87 m)(90.7 m)(91.9 m)(116.1 m)(126.5 m)(128.8 m)(140.2 m)(145.4 m)(151.6 m)(163.6 m)(169.9 m)(179.2 m)(188.7 m)

Total Equity

9.1 m14 m13.6 m10.3 m15.3 m17.1 m41.5 m37.6 m32.8 m24 m19 m14.3 m8.3 m

EPS

0.1 0.2 0.1 0.6 0.4 0.1 0.2 0.2 0.2 0.2 0.2 0.3

Financial Leverage

1.4 x1.7 x1.5 x2.6 x1.8 x1.4 x1.1 x1.2 x1.2 x1.2 x1.2 x1.3 x1.6 x

InVivo Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(18.3 m)(33.3 m)(23.4 m)(26.7 m)

Depreciation and Amortization

752 k689 k553 k395 k

Accounts Payable

(330 k)(48 k)489 k(23 k)

Cash From Operating Activities

(15.3 m)(16.3 m)(16.7 m)(19.7 m)

Purchases of PP&E

(47 k)(5 k)(107 k)(65 k)

Cash From Investing Activities

(2 k)(5 k)(6.5 m)11.5 m

Cash From Financing Activities

14.8 m23.1 m29.8 m(383 k)

Net Change in Cash

(521 k)1.5 m6.5 m

Interest Paid

132 k121 k103 k71 k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(5.1 m)(8.7 m)(10 m)(15.8 m)(26.3 m)(28.6 m)(6.6 m)(11.8 m)(18 m)(6.4 m)(12.7 m)(22.1 m)(4.8 m)

Depreciation and Amortization

195 k378 k568 k178 k352 k527 k146 k284 k417 k135 k264 k387 k40 k

Accounts Payable

(195 k)(307 k)(188 k)224 k384 k228 k(83 k)38 k35 k27 k(133 k)259 k240 k

Cash From Operating Activities

(4.2 m)(7.8 m)(11.1 m)(2.9 m)(7.1 m)(11 m)(4.2 m)(8.3 m)(12.3 m)(6.1 m)(11 m)(15.6 m)(3.7 m)

Purchases of PP&E

(35 k)(5 k)(14 k)(35 k)(5 k)(2 k)(50 k)(73 k)(96 k)(16 k)(54 k)(54 k)

Cash From Investing Activities

(35 k)(5 k)(14 k)(35 k)(5 k)(2 k)(50 k)(73 k)(96 k)(827 k)4 m10.8 m25 k

Cash From Financing Activities

95 k14.7 m14.7 m14 m18.8 m19.7 m29.9 m29.8 m29.9 m(57 k)(153 k)(238 k)2.4 m

Net Change in Cash

(4.1 m)6.9 m3.7 m11.1 m11.7 m8.7 m25.6 m21.4 m10.3 m(7 m)(7.1 m)(5 m)

Interest Paid

32 k65 k77 k33 k64 k97 k28 k54 k76 k20 k40 k56 k14 k

InVivo Therapeutics Ratios

USDY, 2018

Financial Leverage

1.6 x
Report incorrect company information

InVivo Therapeutics Operating Metrics

FY, 2016

Facilities

1

Patents (US)

8

Patents (foreign)

8

Patents Pending

12
Report incorrect company information